TNFSF10 and Miyoshi myopathy: By contrast, since pIL6-TRAIL+-GFP+-UC-MSCs are committed to overexpress TRAIL only in the presence of specific cytokines secreted within the bone MM microenvironment, this cell-based therapy model would be suitable for human studies not only in controlling the marrow MM progression, but also in other osteotropic tumors since preclinical observation confirmed the biosafety of viral-transduced MSCs for TRAIL expression [48].